Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Gauzy Ltd. and Zimmer Biomet Holdings, concerning possible violations of federal securities laws and unlawful business practices [1] Gauzy Ltd. (NASDAQ:GAUZ) - On November 14, 2025, Gauzy announced a delay in releasing its third-quarter financial results due to the initiation of insolvency proceedings for three subsidiaries in France [6] - Following this announcement, Gauzy's stock price dropped by $1.35 per share, a decline of 33.58%, closing at $2.67 per share [6] Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - On November 5, 2025, Zimmer Biomet reported third-quarter net sales of $2 billion, which fell short of consensus estimates of $2.01 billion [6] - The company revised its full-year organic revenue growth outlook to a range of 3.5% to 4%, down from a previous range of 3.5% to 4.5% [6] - Zimmer Biomet experienced weakness in international markets and non-core businesses, with challenges from distributors and order cancellations in the Middle East and Eastern Europe impacting results [6] - Following the earnings report, Zimmer Biomet's stock price fell by $15.63 per share, a decrease of 15.5%, closing at $87.55 per share [6]